Varencicline and Cytisine may reduce smoking and alcohol use (adapted from images by Vaccinationist, Jynto, Penubag and Fry1989 via Wikimedia Commons)
Various smoking cessation therapies are also associated with lower alcohol consumption, conferring a two-pronged benefit in reducing cancer risk. Tindle et al. have published the results of the St PETER HIV trial, which examined a cohort of 400 HIV-positive smokers and heavy alcohol users in Russia to compare how individuals benefit from three different anti-smoking treatments. Two newer treatments, varenicline and cytisine, delivered comparable benefit to conventional nicotine replacement therapy. The authors observed meaningful reduction in both cigarette consumption and the frequency of heavy alcohol use in all trial cohorts, with more than 20% achieving abstinence after three months. These results suggest that all three cessation therapies could be beneficial for this high-risk demographic.
Tindle HA, … Samet JH. JAMA Netw Open. 2022 Aug 1;5(8):e2225129.
Sex disparities...
RSS Feeds